What is Humacyte?
Humacyte, Inc. is a pioneering biotechnology company focused on the development and manufacturing of off-the-shelf, implantable, bioengineered human tissues. Leveraging a proprietary technology platform, the company engineers human acellular vessels (HAVs) designed to integrate seamlessly into the patient's body without triggering adverse immune responses or foreign body reactions. These HAVs are intended to address critical needs in vascular repair, reconstruction, and replacement across various therapeutic areas, including vascular trauma, hemodialysis access, peripheral arterial disease, pediatric heart surgery, and coronary artery bypass grafting. Furthermore, Humacyte's technology holds potential for cellular therapy delivery, such as pancreatic islet cell transplantation for Type 1 diabetes.
How much funding has Humacyte raised?
Humacyte has raised a total of $587.9M across 9 funding rounds:
Series B
$150M
Private Equity
$10M
Unspecified
$14.1M
Other Financing Round
$150M
Debt
$2M
Debt
$50M
Debt
$150M
Series B (2015): $150M supported by Reignwood Group, Access Industries, and Bangkok Bank Public Company Ltd.
Private Equity (2016): $10M featuring California Institute for Regenerative Medicine
Unspecified (2017): $14.1M backed by California Institute of Regenerative Medicine
Other Financing Round (2018): $150M with participation from Fresenius Medical Care
Debt (2020): $2M led by PPP
Debt (2021): $50M supported by Silicon Valley Bank
Debt (2023): $150M featuring Oberland Capital
Key Investors in Humacyte
Reignwood Group
Reignwood Group is a global Chinese enterprise with extensive financial resources and a strategic international platform, investing across a spectrum of industries.
Access Industries
Access Industries is a privately-held industrial conglomerate making strategic global investments, focusing on long-term value creation across diverse sectors including biotechnology and venture capital.
Oberland Capital
Oberland Capital is a private investment firm specializing in flexible financing solutions for innovation within the global healthcare industry, managing significant assets.
What's next for Humacyte?
With the recent infusion of major strategic capital, Humacyte is poised to accelerate its commercialization efforts and expand its clinical applications. The company's focus on developing a portfolio of HAVs for diverse medical needs positions it for significant growth in the regenerative medicine and medical device markets. Future developments will likely center on advancing its manufacturing capabilities, securing regulatory approvals, and forging strategic partnerships to broaden patient access to its innovative tissue-based therapies. The sustained investment indicates strong confidence in Humacyte's technology and its potential to transform treatment paradigms for a range of debilitating diseases.
See full Humacyte company page
